Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PPIA | P62937 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6815544 | 0.89 | LMNA (0.57) | LMNAHPGDSMPD1HDAC1HDAC8 | |
| SCHEMBL8408175 | 0.88 | HPGD (0.56) | LMNAHPGDSMPD1HDAC1HDAC8 | |
| SCHEMBL541510 | 0.87 | HPGD (0.54) | LMNAHPGDSMPD1HDAC1HDAC8 | |
| SCHEMBL2575159 | 0.86 | MAPT (0.64) | LMNAHPGDRAB9AMAPTL3MBTL1 | |
| SCHEMBL3245222 | 0.86 | SMPD1 (0.67) | LMNAHPGDSMPD1HDAC1HDAC8 | |
| SCHEMBL10368672 | 0.85 | MTNR1A (0.56) | LMNAHPGDSMPD1HDAC1HDAC8 | |
| SCHEMBL4001117 | 0.85 | LMNA (0.52) | LMNAHPGDSMPD1HDAC1HDAC8 | |
| SCHEMBL2188210 | 0.83 | SMPD1 (0.76) | LMNAHPGDSMPD1HDAC1HDAC8 | |
| SCHEMBL2063068 | 0.83 | SMN1; SMN2 (0.73) | LMNAHPGDSMPD1HDAC1HDAC8 | |
| SCHEMBL1782909 | 0.83 | HPGD (0.72) | LMNAHPGDSMPD1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1206212-C | Tri-substd. phenyl derivs. and analogues | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | CN | disclosed |
| US-6750252-B2 | FOR USE IN CLINICAL CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2004-06-15 | — | — | US | disclosed |
| EP-1237856-B1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| CN-1402703-A | Tri-substd. phenyl derivs. and analogues | ASTRAZENECA AB (SE) | 2003-03-12 | — | — | CN | disclosed |
| EP-1237856-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040172-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | GPR119, IAPP, INSR | LMNA 1312/4885HPGD 1087/4885SMPD1 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.